Trials / Unknown
UnknownNCT04734912
Evaluation of Transnasal Endoscopy During COVID-19 Pandemic
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Johannes Gutenberg University Mainz · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Patients who received the indication for endoscopic diagnostics using gastroscopy in transnasal technique will be included into the study. The examination is carried out in standard technique and is not influenced by the study. Following the examination, patient data is collected pseudonymously and a questionnaire is submitted to the patient.
Detailed description
COVID-19 is transmitted, among other things, by a droplet infection. Conventional gastroscopy through the patient's mouth is therefore considered a high-risk examination for the medical and nursing staff. Alternatively, gastroscopy can also be performed through the patient's nose. An advantage here is that the aerosol formation is naturally significantly reduced and the patient usually does not need sedation, since in transnasal endoscopy no stranglehold occurs. Transnasal endoscopy therefore appears to us, especially during the COVID-19 pandemic, as a safe alternative to conventional gastroscopy. Patients who received the indication for endoscopic diagnostics using gastroscopy in transnasal technique will be included into the study. The examination is carried out in standard technique and is not influenced by the study. Following the examination, patient data is collected pseudonymously and a questionnaire is sumbitted to the patient. Only patients who have the indication for gastroscopy in transnasal technique are included. A specific risk to patients cannot be foreseen.This study does not interfere with diagnostics or therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | gastroscopy in transnasal techique | All patients with indication for gastroscopy in transnasal technique are included. |
Timeline
- Start date
- 2021-01-13
- Primary completion
- 2021-06-15
- Completion
- 2021-12-31
- First posted
- 2021-02-02
- Last updated
- 2021-02-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04734912. Inclusion in this directory is not an endorsement.